HUMANIGEN INC (HGEN) Stock Price, Forecast & Analysis
USA - NASDAQ:HGEN - US4448632038 - Common Stock
HGEN Key Statistics, Chart & Performance
The current stock price of HGEN is 0.0361 USD. In the past month the price decreased by -76.06%. In the past year, price decreased by -90.16%.
HGEN Latest News, Press Relases and Analysis
HGEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About HGEN
Company Profile
Humanigen, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Short Hills, New Jersey and currently employs 6 full-time employees. The company went IPO on 2013-01-30. The firm is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The firm has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.
Company Info
HUMANIGEN INC
830 Morris Turnpike, 4th Floor
Short Hills NEW JERSEY 94010 US
CEO: Cameron Durrant
Employees: 6
Phone: 19732003100.0
HUMANIGEN INC / HGEN FAQ
What does HGEN do?
Humanigen, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Short Hills, New Jersey and currently employs 6 full-time employees. The company went IPO on 2013-01-30. The firm is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The firm has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.
What is the current price of HGEN stock?
The current stock price of HGEN is 0.0361 USD. The price decreased by -81.12% in the last trading session.
Does HGEN stock pay dividends?
HGEN does not pay a dividend.
How is the ChartMill rating for HUMANIGEN INC?
HGEN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for HGEN stock?
HUMANIGEN INC (HGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.65).
What is the expected growth for HGEN stock?
The Revenue of HUMANIGEN INC (HGEN) is expected to decline by -91.42% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
HGEN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to HGEN. When comparing the yearly performance of all stocks, HGEN is a bad performer in the overall market: 99.57% of all stocks are doing better.
HGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HGEN. HGEN may be in some trouble as it scores bad on both profitability and health.
HGEN Financial Highlights
Over the last trailing twelve months HGEN reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS increased by 79.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
HGEN Forecast & Estimates
6 analysts have analysed HGEN and the average price target is 0.15 USD. This implies a price increase of 323.82% is expected in the next year compared to the current price of 0.0361.
For the next year, analysts expect an EPS growth of 83.55% and a revenue growth -91.42% for HGEN